Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Chemomab Therapeutics awarded new U.S. patent for CM-101 » 07:02
06/28/22
06/28
07:02
06/28/22
07:02
CMMB

Chemomab Therapeutics

$3.99 /

-0.135 (-3.28%)

Chemomab Therapeutics…

Chemomab Therapeutics reported that the United States Patent and Trademark Office has issued a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target at the confluence of fibrosis and inflammation. The new patent covers the use of CM-101 and sequence-related CCL24 antibodies for the treatment of hepatic diseases. CM-101 is currently in a Phase 2 trial for the treatment of primary sclerosing cholangitis, a potentially lethal disease affecting the bile ducts of the liver, as well as a Phase 2 liver fibrosis study.

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$3.99 /

-0.135 (-3.28%)

CMMB Chemomab Therapeutics
$3.99 /

-0.135 (-3.28%)

03/10/22 Oppenheimer
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer
12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
CMMB Chemomab Therapeutics
$3.99 /

-0.135 (-3.28%)

Hot Stocks
Chemomab data supports efficacy of CM-101 in primary sclerosing cholangitis » 08:07
06/27/22
06/27
08:07
06/27/22
08:07
CMMB

Chemomab Therapeutics

$4.12 /

+0.36 (+9.57%)

Chemomab Therapeutics…

Chemomab Therapeutics reported on two recent presentations at important scientific meetings. The presentations included preclinical data that support the role of the soluble protein CCL24 in the pathophysiology of liver diseases such as primary sclerosing cholangitis , and also indicate that Chemomab's CCL24 neutralizing antibody CM-101 demonstrates translatable patterns of extracellular matrix emodeling in preclinical and clinical studies.At EASL: The International Liver Congress 2022, Chemomab presented data from a combination of single-cell and spatial transcriptomics methods that enabled an in-depth analysis of relevant subpopulations and pathways regulated by CCL24 in fibroinflammatory liver disease. The analysis revealed unique resident liver macrophage subpopulations as the major source of CCL24 in the injured peribiliary area in an experimental PSC model. The analysis also showed that treatment with CM-101 interfered with core PSC pathways, including inhibiting ECM-related pathways and the recruitment and presence of monocytes and macrophages. At the First International Extracellular Matrix Pharmacology Conference, Chemomab presented clinical and animal model data2 demonstrating that treatment with its CCL24 neutralizing antibody CM-101 attenuates remodeling of ECM key proteins. ECM deposition is known to be affected by fibroblast activation and epithelial cell activity, key cell populations that have been shown to be involved in the pathophysiology of PSC and that are closely related to CM-101's mechanism of action. Importantly, this dataset supports the translation of these results from relevant animal models into the design of Chemomab's clinical studies assessing CM-101 as a potential treatment for PSC, including potentially applying findings using experimental models of ECM remodeling in the liver to the use of a translatable profile of serum biomarkers in patients. "We welcome the opportunity to present validating data on the central role of CCL24 in the pathophysiology of fibroinflammatory liver disease and the corresponding ability of CM-101 to attenuate key biomarkers associated with this pathophysiology," noted Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab. "These studies are valuable for informing our clinical trials in PSC and other disorders, and for further highlighting the significant potential of our unique approach."

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$4.12 /

+0.36 (+9.57%)

CMMB Chemomab Therapeutics
$4.12 /

+0.36 (+9.57%)

03/10/22 Oppenheimer
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer
12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
CMMB Chemomab Therapeutics
$4.12 /

+0.36 (+9.57%)

Hot Stocks
Chemomab Therapeutics' CM-101 antibody featured in poster presentation at EULAR » 07:10
06/02/22
06/02
07:10
06/02/22
07:10
CMMB

Chemomab Therapeutics

$3.10 /

+0.02 (+0.65%)

Chemomab Therapeutics…

Chemomab Therapeutics reported that data supporting the role of CCL24 as a therapeutic target for systemic sclerosis is being presented in a poster at the EULAR European Congress of Rheumatology. Chemomab's CCL24-neutralizing antibody, CM-101, is expected to enter a Phase 2 trial in systemic sclerosis later this year. The study , examined the role of CCL24 in longitudinal diffuse cutaneous systemic sclerosis - dcSSc -. The findings support the role of CCL24 as a potential therapeutic target, demonstrating elevated serum levels of CCL24 in patients with dcSSc. High CCL24 serum levels were correlated with disease activity and worse prognosis as reflected by high fibrotic activity and deterioration of lung function over time. The authors conclude that the study data reinforces the rationale for assessing the therapeutic utility of a CCL24-neutralizing antibody in systemic sclerosis clinical trials.

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$3.10 /

+0.02 (+0.65%)

CMMB Chemomab Therapeutics
$3.10 /

+0.02 (+0.65%)

03/10/22 Oppenheimer
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer
12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
CMMB Chemomab Therapeutics
$3.10 /

+0.02 (+0.65%)

Earnings
Chemomab Therapeutics reports Q1 EPS (2c) vs. (1c) last year » 06:09
05/12/22
05/12
06:09
05/12/22
06:09
CMMB

Chemomab Therapeutics

$2.61 /

-0.225 (-7.95%)

"During the quarter…

"During the quarter we continued to make good progress in refining and implementing revisions to our CM-101 clinical program aimed at decreasing overall development risk, maximizing the clinical data obtained to facilitate clinical decision-making, and generating critical data to support advancement to registration trials," said Dale Pfost, PhD, Chief Executive Officer of Chemomab. "We are expanding our efforts in primary sclerosing cholangitis with an enlarged clinical trial that is recruiting patients from new sites in the U.S. and Europe, while adding an important dose finding component and an open-label extension. We will be performing an interim analysis of the currently enrolling dose cohort in the PSC study to assess safety and to confirm the planned sample sizes for the CM-101 dose cohorts. This planned interim read-out is expected late this year. In systemic sclerosis, we expect the revised Phase 2 trial design to enable an expedited path to proof-of-concept data, and, importantly, to provide additional information on CM-101's activity in modifying the skin, lung and vascular pathophysiology seen in SSc patients. We are designing this trial with the assistance of key SSc opinion leaders and are on track to launch the trial by the end of the year. I am also pleased to report that we have now completed enrollment in our Phase 2 safety, pharmacokinetic and biomarker liver fibrosis study, with final readouts expected near year's end. We continue to use our capital efficiently and look forward to providing further details on our progress with the PSC and SSc Phase 2 trials this summer."

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$2.61 /

-0.225 (-7.95%)

CMMB Chemomab Therapeutics
$2.61 /

-0.225 (-7.95%)

03/10/22 Oppenheimer
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer
12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
CMMB Chemomab Therapeutics
$2.61 /

-0.225 (-7.95%)

Conference/Events
Oppenheimer healthcare analyst holds an analyst/industry conference call » 13:25
03/22/22
03/22
13:25
03/22/22
13:25
APLS

Apellis

$54.08 /

+1.975 (+3.79%)

, AVTX

Avalo Therapeutics

/

+

, CMMB

Chemomab Therapeutics

$5.26 /

+0.43 (+8.90%)

, CUE

Cue Biopharma

$5.53 /

-0.07 (-1.25%)

, FSTX

F-star Therapeutics

$3.72 /

+0.02 (+0.54%)

, JSPR

Jasper Therapeutics

$3.58 /

+0.08 (+2.29%)

, SGEN

Seagen

$142.47 /

+0.86 (+0.61%)

, TARS

Tarsus Pharmaceuticals

$18.20 /

+0.63 (+3.59%)

, VBLT

VBL Therapeutics

$1.47 /

-0.03 (-2.00%)

, ZNTL

Zentalis

$50.79 /

+1.82 (+3.72%)

Healthcare Analyst Holz,…

Healthcare Analyst Holz, along with the Biotech & Healthcare Analyst Research Teams, (relevant tickers include: APLS, AVTX, CMMB, CUE, FSTX, JSPR, SGEN, TARS, VBLT and ZNTL) discuss their list of 10 top ideas and takeaways from the recently held 32nd Annual Healthcare Conference on an Analyst/Industry conference call to be held on March 22 at 2 pm.

ShowHide Related Items >><<
ZNTL Zentalis
$50.79 /

+1.82 (+3.72%)

VBLT VBL Therapeutics
$1.47 /

-0.03 (-2.00%)

TARS Tarsus Pharmaceuticals
$18.20 /

+0.63 (+3.59%)

SGEN Seagen
$142.47 /

+0.86 (+0.61%)

JSPR Jasper Therapeutics
$3.58 /

+0.08 (+2.29%)

FSTX F-star Therapeutics
$3.72 /

+0.02 (+0.54%)

CUE Cue Biopharma
$5.53 /

-0.07 (-1.25%)

CMMB Chemomab Therapeutics
$5.26 /

+0.43 (+8.90%)

AVTX Avalo Therapeutics
/

+

APLS Apellis
$54.08 /

+1.975 (+3.79%)

APLS Apellis
$54.08 /

+1.975 (+3.79%)

03/17/22 Citi
Apellis added to 'US Focus List,' price target raised to $81 at Citi
03/16/22 Baird
Apellis price target raised to $90 from $83 at Baird
01/11/22 Raymond James
Apellis price target lowered to $112 from $116 at Raymond James
01/06/22 Goldman Sachs
Apellis price target raised to $102 from $100 at Goldman Sachs
AVTX Avalo Therapeutics
/

+

03/03/22 Jefferies
Avalo Therapeutics cut to Hold at Jefferies after pipeline reprioritization
03/03/22 Jefferies
Avalo Therapeutics downgraded to Hold from Buy at Jefferies
09/24/21 RBC Capital
Avalo Therapeutics initiated with an Outperform at RBC Capital
CMMB Chemomab Therapeutics
$5.26 /

+0.43 (+8.90%)

03/10/22 Oppenheimer
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer
12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CUE Cue Biopharma
$5.53 /

-0.07 (-1.25%)

03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
01/03/22 Craig-Hallum
Cue Biopharma initiated with a Buy at Craig-Hallum
FSTX F-star Therapeutics
$3.72 /

+0.02 (+0.54%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Securities
F-star Therapeutics initiated with an Outperform at SVB Leerink
06/09/21 B. Riley
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside
JSPR Jasper Therapeutics
$3.58 /

+0.08 (+2.29%)

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
SGEN Seagen
$142.47 /

+0.86 (+0.61%)

02/24/22 Piper Sandler
Seagen's tisotumab vedotin shows 'modest signal of activity,' says Piper Sandler
02/16/22 JMP Securities
Seagen price target lowered to $142 from $201 at JMP Securities
02/11/22 Oppenheimer
Seagen price target lowered to $162 from $198 at Oppenheimer
02/10/22 Stifel
Seagen price target lowered to $145 from $180 at Stifel
TARS Tarsus Pharmaceuticals
$18.20 /

+0.63 (+3.59%)

12/21/21
Fly Intel: Top five analyst initiations
12/21/21 H.C. Wainwright
Tarsus Pharmaceuticals initiated with a Buy at H.C. Wainwright
11/22/21 Oppenheimer
Tarsus Pharmaceuticals initiated with an Outperform at Oppenheimer
10/07/21 Raymond James
Tarsus Pharmaceuticals price target raised to $65 from $50 at Raymond James
VBLT VBL Therapeutics
$1.47 /

-0.03 (-2.00%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
ZNTL Zentalis
$50.79 /

+1.82 (+3.72%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Securities
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$50.79 /

+1.82 (+3.72%)

VBLT VBL Therapeutics
$1.47 /

-0.03 (-2.00%)

SGEN Seagen
$142.47 /

+0.86 (+0.61%)

JSPR Jasper Therapeutics
$3.58 /

+0.08 (+2.29%)

FSTX F-star Therapeutics
$3.72 /

+0.02 (+0.54%)

CMMB Chemomab Therapeutics
$5.26 /

+0.43 (+8.90%)

AVTX Avalo Therapeutics
/

+

APLS Apellis
$54.08 /

+1.975 (+3.79%)

  • 16
    Nov
  • 15
    Sep
  • 29
    Jun
  • 09
    May
  • 09
    Apr
AVTX Avalo Therapeutics
/

+

SGEN Seagen
$142.47 /

+0.86 (+0.61%)

JSPR Jasper Therapeutics
$3.58 /

+0.08 (+2.29%)

TARS Tarsus Pharmaceuticals
$18.20 /

+0.63 (+3.59%)

JSPR Jasper Therapeutics
$3.58 /

+0.08 (+2.29%)

APLS Apellis
$54.08 /

+1.975 (+3.79%)

Conference/Events
Oppenheimer healthcare analyst holds an analyst/industry conference call » 09:16
03/22/22
03/22
09:16
03/22/22
09:16
APLS

Apellis

$52.11 /

-0.775 (-1.47%)

, AVTX

Avalo Therapeutics

/

+

, CMMB

Chemomab Therapeutics

$4.83 /

+0.36 (+8.05%)

, CUE

Cue Biopharma

$5.61 /

+0.01 (+0.18%)

, FSTX

F-star Therapeutics

$3.70 /

-0.01 (-0.27%)

, JSPR

Jasper Therapeutics

$3.48 /

-0.02 (-0.57%)

, SGEN

Seagen

$141.54 /

-1.33 (-0.93%)

, TARS

Tarsus Pharmaceuticals

$17.55 /

-0.41 (-2.28%)

, VBLT

VBL Therapeutics

$1.48 /

+0.025 (+1.72%)

, ZNTL

Zentalis

$48.97 /

-1.38 (-2.74%)

Healthcare Analyst Holz,…

Healthcare Analyst Holz, along with the Biotech & Healthcare Analyst Research Teams, (relevant tickers include: APLS, AVTX, CMMB, CUE, FSTX, JSPR, SGEN, TARS, VBLT and ZNTL) discuss their list of 10 top ideas and takeaways from the recently held 32nd Annual Healthcare Conference on an Analyst/Industry conference call to be held on March 22 at 2 pm.

ShowHide Related Items >><<
ZNTL Zentalis
$48.97 /

-1.38 (-2.74%)

VBLT VBL Therapeutics
$1.48 /

+0.025 (+1.72%)

TARS Tarsus Pharmaceuticals
$17.55 /

-0.41 (-2.28%)

SGEN Seagen
$141.54 /

-1.33 (-0.93%)

JSPR Jasper Therapeutics
$3.48 /

-0.02 (-0.57%)

FSTX F-star Therapeutics
$3.70 /

-0.01 (-0.27%)

CUE Cue Biopharma
$5.61 /

+0.01 (+0.18%)

CMMB Chemomab Therapeutics
$4.83 /

+0.36 (+8.05%)

AVTX Avalo Therapeutics
/

+

APLS Apellis
$52.11 /

-0.775 (-1.47%)

APLS Apellis
$52.11 /

-0.775 (-1.47%)

03/17/22 Citi
Apellis added to 'US Focus List,' price target raised to $81 at Citi
03/16/22 Baird
Apellis price target raised to $90 from $83 at Baird
01/11/22 Raymond James
Apellis price target lowered to $112 from $116 at Raymond James
01/06/22 Goldman Sachs
Apellis price target raised to $102 from $100 at Goldman Sachs
AVTX Avalo Therapeutics
/

+

03/03/22 Jefferies
Avalo Therapeutics cut to Hold at Jefferies after pipeline reprioritization
03/03/22 Jefferies
Avalo Therapeutics downgraded to Hold from Buy at Jefferies
09/24/21 RBC Capital
Avalo Therapeutics initiated with an Outperform at RBC Capital
CMMB Chemomab Therapeutics
$4.83 /

+0.36 (+8.05%)

03/10/22 Oppenheimer
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer
12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CUE Cue Biopharma
$5.61 /

+0.01 (+0.18%)

03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
01/03/22 Craig-Hallum
Cue Biopharma initiated with a Buy at Craig-Hallum
FSTX F-star Therapeutics
$3.70 /

-0.01 (-0.27%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Securities
F-star Therapeutics initiated with an Outperform at SVB Leerink
06/09/21 B. Riley
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside
JSPR Jasper Therapeutics
$3.48 /

-0.02 (-0.57%)

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
SGEN Seagen
$141.54 /

-1.33 (-0.93%)

02/24/22 Piper Sandler
Seagen's tisotumab vedotin shows 'modest signal of activity,' says Piper Sandler
02/16/22 JMP Securities
Seagen price target lowered to $142 from $201 at JMP Securities
02/11/22 Oppenheimer
Seagen price target lowered to $162 from $198 at Oppenheimer
02/10/22 Stifel
Seagen price target lowered to $145 from $180 at Stifel
TARS Tarsus Pharmaceuticals
$17.55 /

-0.41 (-2.28%)

12/21/21
Fly Intel: Top five analyst initiations
12/21/21 H.C. Wainwright
Tarsus Pharmaceuticals initiated with a Buy at H.C. Wainwright
11/22/21 Oppenheimer
Tarsus Pharmaceuticals initiated with an Outperform at Oppenheimer
10/07/21 Raymond James
Tarsus Pharmaceuticals price target raised to $65 from $50 at Raymond James
VBLT VBL Therapeutics
$1.48 /

+0.025 (+1.72%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
ZNTL Zentalis
$48.97 /

-1.38 (-2.74%)

11/11/21 H.C. Wainwright
Zentalis price target raised to $120 from $80 at H.C. Wainwright
10/28/21 SVB Securities
Zentalis price target raised to $84 from $64 at SVB Leerink
10/27/21 Wedbush
Zentalis price target raised to $89 from $65 at Wedbush
10/19/21 Morgan Stanley
Zentalis assumed with an Overweight at Morgan Stanley
ZNTL Zentalis
$48.97 /

-1.38 (-2.74%)

VBLT VBL Therapeutics
$1.48 /

+0.025 (+1.72%)

SGEN Seagen
$141.54 /

-1.33 (-0.93%)

JSPR Jasper Therapeutics
$3.48 /

-0.02 (-0.57%)

FSTX F-star Therapeutics
$3.70 /

-0.01 (-0.27%)

CMMB Chemomab Therapeutics
$4.83 /

+0.36 (+8.05%)

AVTX Avalo Therapeutics
/

+

APLS Apellis
$52.11 /

-0.775 (-1.47%)

  • 16
    Nov
  • 15
    Sep
  • 29
    Jun
  • 09
    May
  • 09
    Apr
AVTX Avalo Therapeutics
/

+

SGEN Seagen
$141.54 /

-1.33 (-0.93%)

JSPR Jasper Therapeutics
$3.48 /

-0.02 (-0.57%)

TARS Tarsus Pharmaceuticals
$17.55 /

-0.41 (-2.28%)

JSPR Jasper Therapeutics
$3.48 /

-0.02 (-0.57%)

APLS Apellis
$52.11 /

-0.775 (-1.47%)

Recommendations
Chemomab Therapeutics price target lowered to $20 from $30 at Oppenheimer » 06:23
03/10/22
03/10
06:23
03/10/22
06:23
CMMB

Chemomab Therapeutics

$3.80 /

+0.22 (+6.15%)

Oppenheimer analyst Jeff…

Oppenheimer analyst Jeff Jones lowered the firm's price target on Chemomab Therapeutics to $20 from $30 and keeps an Outperform rating on the shares, with shares down more than 40% year-to-date as the biotech markets have continued to weaken. The analyst notes the company provided a year-end update which included highlights from an extensive revision to CM-101 clinical plans. Jones sees this news as improving the robustness of the clinical development effort, but also as delaying commercialization for both PSC and SSC. A more in-depth update on clinical plans is anticipated in May, he adds.

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$3.80 /

+0.22 (+6.15%)

CMMB Chemomab Therapeutics
$3.80 /

+0.22 (+6.15%)

12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CMMB Chemomab Therapeutics
$3.80 /

+0.22 (+6.15%)

Earnings
Chemomab Therapeutics reports Q4 EPS (2c), consensus (10c) » 06:04
03/09/22
03/09
06:04
03/09/22
06:04
CMMB

Chemomab Therapeutics

$3.55 /

+0.28 (+8.56%)

Cash, cash equivalents…

Cash, cash equivalents and short-term bank deposits were $61.2M as of December 31, 2021, compared to $11.8M as of December 31, 2020. "2021 was a transformational year for Chemomab as we became a public company, launched two Phase 2 trials and expanded our management team to include highly experienced biotech executives from the U.S.," said Dale Pfost, CEO of Chemomab. "With this foundation in place, we conducted a comprehensive review of our clinical programs, which recommended significant changes designed to achieve biological and pharmacological validation for CM-101 sooner and to prepare us to advance to registrational trials in as capital and time-efficient a manner as possible. Overall, we believe that these changes will sharpen our focus on our clinical efforts in PSC and SSC, and accelerate the timelines, particularly in SSc, to achieve meaningful mechanistic, biological and clinical proof of concept data. These revisions are expected to provide more clinical data read-outs over the next 24 months-we anticipate 3-4 data readouts compared to the two previously planned. They are also expected to decrease our capital requirements and enable us to extend our cash runway by about six months through to the end of 2023. We are excited about moving forward with this revised clinical program and look forward to providing more detail on our plans in the next few months."

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$3.55 /

+0.28 (+8.56%)

CMMB Chemomab Therapeutics
$3.55 /

+0.28 (+8.56%)

12/07/21 Aegis
Chemomab Therapeutics initiated with a Buy at Aegis
05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CMMB Chemomab Therapeutics
$3.55 /

+0.28 (+8.56%)

Initiation
Chemomab Therapeutics initiated with a Buy at Aegis » 10:58
12/07/21
12/07
10:58
12/07/21
10:58
CMMB

Chemomab Therapeutics

$8.15 /

+0.72 (+9.69%)

Aegis analyst Nathan…

Aegis analyst Nathan Weinstein initiated coverage of Chemomab Therapeutics with a Buy rating and $30 price target.

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$8.15 /

+0.72 (+9.69%)

CMMB Chemomab Therapeutics
$8.15 /

+0.72 (+9.69%)

05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CMMB Chemomab Therapeutics
$8.15 /

+0.72 (+9.69%)

Hot Stocks
Chemomab Therapeutics names David Weiner, MD as Interim Chief Medical Officer » 08:02
12/03/21
12/03
08:02
12/03/21
08:02
CMMB

Chemomab Therapeutics

$8.42 /

-0.095 (-1.12%)

Chemomab Therapeutics…

Chemomab Therapeutics announced that David Weiner, MD has been named Interim Chief Medical Officer, effective immediately. This position will be in a part-time capacity. Dr. Weiner is replacing Dr. Arnon Aharon, who has resigned. Dr. Aharon intends to continue at Chemomab for the next 60 days and as a senior medical advisor thereafter to ensure a seamless transition. Weiner, who is based in the U.S., has more than 25 years of experience in the discovery and clinical development of novel therapeutics and has held senior executive roles at private and public biotechnology companies.

ShowHide Related Items >><<
CMMB Chemomab Therapeutics
$8.42 /

-0.095 (-1.12%)

CMMB Chemomab Therapeutics
$8.42 /

-0.095 (-1.12%)

05/26/21 Cantor Fitzgerald
Chemomab Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/07/21 Oppenheimer
Chemomab Therapeutics initiated with an Outperform at Oppenheimer
CMMB Chemomab Therapeutics
$8.42 /

-0.095 (-1.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.